Jami Rubin is a Venture Partner at ARCH Venture Partners working to develop new investment opportunities and advising portfolio companies in strategic transactions. Jami has spent more than 30 years in the biopharma industry as a long time biopharma analyst, investment banker, board member, and executive operator. Most recently, she was CFO of EQRx where she led the December 2021 public offering process raising $1.35 billion in total capital, guided key strategic decision-making, and built a world class finance organization. She is a former partner at Goldman Sachs where she was ranked as a top pharmaceutical analyst, and was a partner at PJT Partners. Over the course of her career, she played a key role in significant corporate transactions, including spin-outs and M&A, with leading pharmaceutical companies including Pfizer, Abbott, AbbVie, Eli Lilly, and Mylan. Jami serves as an Independent Board member and Audit Chair of Relay Therapeutics and holds a BA in History from Vassar College.